Wohlfarth K - Search Results

1

The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products.

Kutschenko A, Bigalke H, Wegner F, Wohlfarth K. Kutschenko A, et al. Among authors: wohlfarth k. Toxicon. 2019 Oct;168:158-163. doi: 10.1016/j.toxicon.2019.07.005. Epub 2019 Jul 16. Toxicon. 2019. PMID: 31323228

2

Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.

Kutschenko A, Weisemann J, Kollewe K, Fiedler T, Alvermann S, Böselt S, Escher C, Garde N, Gingele S, Kaehler SB, Karatschai R, Krüger THC, Sikorra S, Tacik P, Wegner F, Wollmann J, Bigalke H, Wohlfarth K, Rummel A. Kutschenko A, et al. Among authors: wohlfarth k. Clin Neurophysiol. 2019 Jun;130(6):1066-1073. doi: 10.1016/j.clinph.2019.02.007. Epub 2019 Feb 28. Clin Neurophysiol. 2019. PMID: 30871800

3

Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?

Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Lange O, et al. Among authors: wohlfarth k. Clin Neuropharmacol. 2009 Jul-Aug;32(4):213-8. doi: 10.1097/WNF.0b013e3181914d0a. Clin Neuropharmacol. 2009. PMID: 19620852

4

Botulinum A toxins: units versus units.

Wohlfarth K, Göschel H, Frevert J, Dengler R, Bigalke H. Wohlfarth K, et al. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):335-40. doi: 10.1007/pl00004951. Naunyn Schmiedebergs Arch Pharmacol. 1997. PMID: 9089663 Clinical Trial.

5

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Göschel H, et al. Among authors: wohlfarth k. Exp Neurol. 1997 Sep;147(1):96-102. doi: 10.1006/exnr.1997.6580. Exp Neurol. 1997. PMID: 9294406 Clinical Trial.

6

Botulinum A toxin: Dysport improvement of biological availability.

Bigalke H, Wohlfarth K, Irmer A, Dengler R. Bigalke H, et al. Among authors: wohlfarth k. Exp Neurol. 2001 Mar;168(1):162-70. doi: 10.1006/exnr.2000.7583. Exp Neurol. 2001. PMID: 11170731 Clinical Trial.

7

Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.

Rollnik JD, Wohlfarth K, Dengler R, Bigalke H. Rollnik JD, et al. Among authors: wohlfarth k. Neurol Clin Neurophysiol. 2001;2001(3):2-4. doi: 10.1162/152687401300343571. Neurol Clin Neurophysiol. 2001. PMID: 12396862 Clinical Trial.

8

Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.

Wohlfarth K, Kampe K, Bigalke H. Wohlfarth K, et al. Mov Disord. 2004 Mar;19 Suppl 8:S65-7. doi: 10.1002/mds.20012. Mov Disord. 2004. PMID: 15027057 Clinical Trial.

9

Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.

Rollnik JD, Matzke M, Wohlfarth K, Dengler R, Bigalke H. Rollnik JD, et al. Among authors: wohlfarth k. Eur Neurol. 2000;43(1):9-12. doi: 10.1159/000008121. Eur Neurol. 2000. PMID: 10601802 Clinical Trial.

10

Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study.

Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K. Blersch W, et al. Among authors: wohlfarth k. J Neurol Sci. 2002 Dec 15;205(1):59-63. doi: 10.1016/s0022-510x(02)00313-1. J Neurol Sci. 2002. PMID: 12409185 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters